Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
In the latest session, Pulmonx Corp (NASDAQ: LUNG) closed at $2.28 up 2.70% from its previous closing price of $2.22. In other words, the price has increased by $2.70 from its previous closing price. On the day, 0.17 million shares were traded. LUNG stock price reached its highest trading level at $2.28 during the session, while it also had its lowest trading level at $2.19.
Ratios:
For a deeper understanding of Pulmonx Corp’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.15 and its Current Ratio is at 4.86. In the meantime, Its Debt-to-Equity ratio is 0.94 whereas as Long-Term Debt/Eq ratio is at 0.92.
On March 10, 2025, D. Boral Capital started tracking the stock assigning a Buy rating and target price of $17.
Citigroup Downgraded its Buy to Neutral on December 11, 2024, whereas the target price for the stock was revised from $17 to $7.50.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 08 ’25 when Florin Daniel P sold 23,321 shares for $1.99 per share. The transaction valued at 46,409 led to the insider holds 93,910 shares of the business.
DANIEL P FLORIN bought 23,321 shares of LUNG for $46,385 on Dec 08 ’25. On Dec 01 ’25, another insider, French Glendon E. III, who serves as the President and CEO of the company, sold 8,805 shares for $1.57 each. As a result, the insider received 13,824 and left with 277,324 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LUNG now has a Market Capitalization of 94043232 and an Enterprise Value of 74058240. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.03 while its Price-to-Book (P/B) ratio in mrq is 1.57. Its current Enterprise Value per Revenue stands at 0.808 whereas that against EBITDA is -1.321.
Stock Price History:
The Beta on a monthly basis for LUNG is 0.14, which has changed by -0.6773256 over the last 52 weeks, in comparison to a change of 0.14446163 over the same period for the S&P500. Over the past 52 weeks, LUNG has reached a high of $9.37, while it has fallen to a 52-week low of $1.31. The 50-Day Moving Average of the stock is 20.67%, while the 200-Day Moving Average is calculated to be -22.98%.
Shares Statistics:
For the past three months, LUNG has traded an average of 2.63M shares per day and 1028730 over the past ten days. A total of 41.25M shares are outstanding, with a floating share count of 36.04M. Insiders hold about 12.63% of the company’s shares, while institutions hold 77.77% stake in the company. Shares short for LUNG as of 1764288000 were 2526582 with a Short Ratio of 1.17, compared to 1761868800 on 2354143. Therefore, it implies a Short% of Shares Outstanding of 2526582 and a Short% of Float of 8.92.
Earnings Estimates
Currently, 6.0 analysts are dedicated to thoroughly evaluating and rating the performance of Pulmonx Corp (LUNG) in the stock market.The consensus estimate for the next quarter is -$0.34, with high estimates of -$0.3 and low estimates of -$0.39.
Analysts are recommending an EPS of between -$1.43 and -$1.49 for the fiscal current year, implying an average EPS of -$1.46. EPS for the following year is -$1.34, with 6.0 analysts recommending between -$1.22 and -$1.55.
Revenue Estimates
A total of 6 analysts believe the company’s revenue will be $21.73M this quarter.It ranges from a high estimate of $23M to a low estimate of $21.1M. As of. The current estimate, Pulmonx Corp’s year-ago sales were $23.77MFor the next quarter, 6 analysts are estimating revenue of $22.65M. There is a high estimate of $24.64M for the next quarter, whereas the lowest estimate is $21.6M.
A total of 6 analysts have provided revenue estimates for LUNG’s current fiscal year. The highest revenue estimate was $90.9M, while the lowest revenue estimate was $89M, resulting in an average revenue estimate of $89.63M. In the same quarter a year ago, actual revenue was $83.79MBased on 6 analysts’ estimates, the company’s revenue will be $94.23M in the next fiscal year. The high estimate is $98.54M and the low estimate is $90.6M.
